Clinical trials: Partial Seizure
Epilepsy
Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic…
- Trial name
- NCT00334958
- Testing
- Rufinamide
- Where
- 77 sites in United States
- Volunteers
- 356 people
- Sponsor
- Eisai Inc.
Epilepsy
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of lacosamide (LCM) in pediatric subjects.
- Trial name
- NCT01964560
- Testing
- Lacosamide
- Where
- 141 sites in United States, Argentina and 33 more
- Volunteers
- 540 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Partial Epilepsy, Catamenial Epilepsy
A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
- Trial name
- NCT00465517
- Testing
- Ganaxolone
- Where
- 27 sites in United States
- Volunteers
- 147 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
The purpose of the study is to evaluate the efficacy and safety of topiramate in epilepsy patients with difficult to treat, partial-onset seizures who are taking one or two standard antiepileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236873
- Testing
- topiramate
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
- Trial name
- NCT00419094
- Testing
- Keppra XR
- Where
- 45 sites in United States, Mexico and 2 more
- Volunteers
- 228 people
- Sponsor
- UCB Pharma
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures
- Trial name
- NCT00988429
- Testing
- 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate
- Where
- 162 sites in United States, Argentina and 9 more
- Volunteers
- 653 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Focal Seizures
A Study of GWP42006 in People With Focal Seizures - Part A
To evaluate the pharmacokinetics, safety and tolerability of GWP42006 compared with placebo, in the presence of other antiepileptic drugs (AEDs).
- Trial name
- NCT02369471
- Testing
- GWP42006
- Where
- 9 sites in Czechia, Spain and 1 more
- Volunteers
- 32 people
- Sponsor
- Jazz Pharmaceuticals
Partial Onset Seizures
Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures
This study will assess the efficacy and safety of BGG492 as adjunctive treatment in patients with partial onset seizures.
- Trial name
- NCT01147003
- Testing
- Investigational new drug, company code: BGG492
- Where
- 51 sites in United States, Bulgaria and 8 more
- Volunteers
- 93 people
- Sponsor
- Novartis
Partial Onset Seizures, Epilepsy
A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
The purpose of this study is to assess the safety of perampanel in the treatment of partial onset seizures in participants of age 12 years and older with epilepsy.
- Trial name
- NCT03836924
- Testing
- Perampanel
- Where
- 12 sites in India
- Volunteers
- 200 people
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
Epilepsy
GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin
- Trial name
- NCT00567424
- Testing
- GW273225
- Where
- 30 sites in United States
- Sponsor
- GlaxoSmithKline
Epilepsy; Seizure, Focal Epilepsy
Seizures Detection in Real Life Setting
Epilepsy is a disabling neurological disease that affects tens of millions of people worldwide. Despite therapeutic advances, about a third of these patients suffer from treatment-resistant forms of epilepsy and still experience…
- Trial name
- ECEME (NCT05635396)
- Testing
- Wearable, non invasive sensor for seizure detection
- Volunteers
- 12 people
- Sponsor
- Reliev Technologies
Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
The objective of this study is to identify the following in adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive…
- Trial name
- FYC02T (NCT03059381)
- Testing
- Fycompa
- Where
- 2 sites in Japan
- Volunteers
- 519 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy
Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures
To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.
- Trial name
- NCT00419393
- Testing
- Keppra XR (Levetiracetam XR)
- Where
- 35 sites in United States, Mexico and 2 more
- Volunteers
- 190 people
- Sponsor
- UCB Pharma
Partial Onset Seizures
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to <4 years of age with refractory partial onset seizures.
- Trial name
- NCT02072824
- Testing
- Pregabalin Dose Level 1, Pregabalin Dose Level 2
- Where
- 72 sites in United States, Belarus and 21 more
- Volunteers
- 175 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Seizure Disorder, Partial
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.
- Trial name
- NCT00141388
- Testing
- Pregabalin
- Where
- 56 sites in United States, Canada
- Volunteers
- 455 people
- Sponsor
- Pfizer
Focal Onset Seizures
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
- Trial name
- NCT06798896
- Testing
- SPN-817
- Where
- 63 sites in United States, Australia and 3 more
- Volunteers
- 216 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).
- Trial name
- BRITE™ (NCT01339559)
- Testing
- Brivaracetam
- Where
- 184 sites in United States, Austria and 26 more
- Volunteers
- 767 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
The objective of this study is to identify the following in adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive…
- Trial name
- FYC01S (NCT03059329)
- Testing
- Fycompa
- Where
- 2 sites in Japan
- Volunteers
- 3,809 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy, Focal-Onset Seizure
A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy
The purpose of this trial is to evaluate the efficacy, safety, and pharmaco-economics of Lacosamide Tablet as first add-on therapy for uncontrolled focal onset epilepsy ,invetigating effects of lacosamide Tablet on cognitive…
- Trial name
- NCT04737837
- Testing
- lacosamide
- Where
- 19 sites in China
- Volunteers
- 200 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Idiopathic Generalized Epilepsy, Partial Onset Seizures
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial…
- Conditions
- Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures
- Trial name
- NCT04252846
- Testing
- Perampanel
- Where
- 36 sites in Denmark, France and 5 more
- Volunteers
- 191 people
- Sponsor
- Eisai Limited